At $183.99, KLA Corporation (NASDAQ:KLAC | KLAC Price Prediction) looks compelling at current levels. The stock has fallen 14.2% over the past month even as management raised its outlook on the two fastest-growing corners of the semiconductor equipment market, creating a rare dislocation in a stock that rarely goes on sale.
KLA sells the inspection, metrology, and process-control tools that chipmakers rely on to keep yields high as transistor geometries shrink. Management says the company runs at roughly 6x its nearest rival in overall process-control share, giving it a near-monopoly position on a segment that grows faster than the underlying market as complexity rises.
The pullback traces to renewed anxiety about U.S. export controls on China and a broad rotation out of semi-cap names, not to any deterioration in the business. Fiscal Q4 revenue reached $3.66 billion, up 15.21% year over year, with non-GAAP EPS of $1.05 beating expectations, the fifth consecutive beat.
Why the Dip Looks Like an Invitation
Management raised its calendar 2026 wafer-equipment market outlook to the low $150 billion range and lifted advanced-packaging systems revenue guidance to roughly $1.1 billion, growth of more than 70% year over year. CEO Rick Wallace said “momentum across our business accelerating in the second half of calendar 2026 and continuing through 2027.”
The service business anchors the model. Services revenue hit $820 million, up 17% year over year, with roughly 80% under contract. Fabs must run inspection tools around the clock regardless of the equipment cycle, which softens downturns. Capital intensity per wafer also rises at each successive node, so process-control spend expands faster than baseline WFE growth. Shares trade at a 34 forward P/E, well below the 50 trailing multiple as earnings scale into guidance.
Where the Bear Case Bites
KLA carries real China risk. Management acknowledged that competitors have shifted into fabs in China KLA cannot serve, and any tightening of Bureau of Industry and Security rules would compress the addressable market. Gross margin of 62.4% is absorbing tariff headwinds and memory-pricing pressure that may persist through 2027.
Insider activity adds caution. In August, the CEO, CFO, and multiple executive officers executed sizable open-market disposals, including a 87,568-share sale by Wallace at $198.95. Free cash flow slipped, with Q4 FCF of $817 million, down 23.24% year over year as working capital funds the ramp.
Reasons to Wait
KLA is not obviously cheap. A 17.7 price-to-sales ratio and 38 price-to-book leave little margin for a cyclical stumble. With shares up 51.99% year to date and 112.04% over one year, a patient investor could wait for the September quarter print to confirm the accelerating second-half thesis before committing.
What the Numbers Say
KLAC trades at $183.99 against a consensus analyst target of $231.78, implying meaningful upside. Coverage skews constructive, with 5 strong buy, 13 buy, 11 hold, and 0 sell ratings across 29 analysts.
KLAC is up 51.99% year to date while the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) has moved from 729.46 at the Q4 filing to 765.72 currently. Shares sit well below the 50-day moving average of $220.07 and closer to the 200-day of $168.52.
Why the Selloff Is the Opportunity
At $183.99, the setup looks attractive. Q1 FY2027 guidance calls for revenue of $4.0 billion plus or minus $200 million and non-GAAP EPS of $1.16 plus or minus $0.10. Management expects second-half calendar 2026 growth of roughly 20% over the first half, with backlog around $12.5 billion.
The risk/reward at a 34 forward P/E favors buyers. Advanced packaging alone is expected to grow almost two times faster than the market, and HBM plus EUV-driven DRAM intensity should carry process-control demand into calendar 2027. The company returned $876.33 million to shareholders in Q4 and just added a $7 billion buyback authorization.
What would invalidate the thesis: a broader China export-control escalation that cuts guidance, or a September-quarter miss that breaks the beat streak. Absent that, the setup pairs an accelerating end market with a stock trading nearly 40% below its 52-week high of $307.03. Buying the dominant process-control franchise during an AI capex acceleration, at a discount to its own recent multiple, is a research-worthy setup at this price.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks